Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$36.28

-1.01 (-2.71%)

11:00
11/29/16
11/29
11:00
11/29/16
11:00

Baird sees strong launch for Sarepta after surveying neurologists

After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.

SRPT Sarepta
$36.28

-1.01 (-2.71%)

10/27/16
PIPR
10/27/16
NO CHANGE
PIPR
Overweight
Piper cuts sales estimates for Sarepta's Exondys51
After management of Sarepta Therapeutics guided that reimbursement typically takes 30-90 days, Piper Jaffray analyst Edward Tenthoff cut his U.S. Exondys51 forecast to $4.5M from $21.5M in Q4 and to $274M from $330M in 2017. The analyst continues to project peak U.S. sales of greater than $500M. He reiterates an Overweight rating on shares of Sarepta with a $68 price atregt following the company's Q3 results. The stock is down 9%, or $3.84, to $40.70 in afternoon trading.
10/27/16
FBCO
10/27/16
NO CHANGE
Target $68
FBCO
Outperform
Sarepta reimbursement concerns overdone, says Credit Suisse
Credit Suisse analyst Alethia Young believes Sarepta Exondys 51 reimbursement concerns are "quite overdone" and notes payer negotiation is inline with what the company has seen in other rare disease drugs launch. Young rates Sarepta an Outperform with a $68 price target.
10/27/16
WEDB
10/27/16
NO CHANGE
Target $72
WEDB
Outperform
Sarepta selloff overdone, says Wedbush
Wedbush analyst Heather Behanna said the selloff in Sarepta is overdone and recommends shares ahead of the Exondys 51 launch update in January. The analyst has an Outperform rating and a $72 price target on Sarepta shares.
11/11/16
LEER
11/11/16
NO CHANGE
Target $55
LEER
Market Perform
Sarepta Exondys 51 launch expectations seem too high for 2017, says Leerink
Leerink analyst Joseph Schwartz believes Sarepta Exondys 51 launch expectations may be too high for 2017. While nothing that a true Duchenne muscular dystrophy prevalence remains unknown, the analyst says that a "start form" number of about 200 patients would need to be provided in early January in order for investors to be confident in 2017 consensus sales estimates of $215M. Additionally, Schwartz points out that based on the price of Exondys 51 per vial, it currently appears that management has underestimated the true price of the drug which they will realize.

TODAY'S FREE FLY STORIES

01:45
09/21/18
09/21
01:45
09/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap: Stock…

AYI

Acuity Brands

$161.46

3.9 (2.48%)

21:35
09/20/18
09/20
21:35
09/20/18
21:35
Upgrade
Acuity Brands rating change at Wells Fargo »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

TTNP

Titan Pharmaceuticals

$0.50

-0.08 (-13.79%)

21:34
09/20/18
09/20
21:34
09/20/18
21:34
Syndicate
Titan Pharmaceuticals raises $9.5M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTEM

Molecular Templates

$5.81

-0.44 (-7.04%)

21:31
09/20/18
09/20
21:31
09/20/18
21:31
Syndicate
Molecular Templates 8.2M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

YMAB

Y-mAbs Therapeutics

$0.00

(0.00%)

21:30
09/20/18
09/20
21:30
09/20/18
21:30
Syndicate
Y-mAbs Therapeutics 6M share IPO priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VKTX

Viking Therapeutics

$18.92

-0.72 (-3.67%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Viking Therapeutics 9.5M share Secondary priced at $18.50 »

William Blair, SunTrust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TWIN

Twin Disc

$23.33

0.34 (1.48%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Twin Disc 1.333M share Secondary priced at $22.50 »

Baird and Oppenheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

FTCH

Farfetch

$0.00

(0.00%)

21:26
09/20/18
09/20
21:26
09/20/18
21:26
Syndicate
Farfetch 44.244M share IPO priced at $20.00, above the range »

Goldman Sachs, JPMorgan,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

21:25
09/20/18
09/20
21:25
09/20/18
21:25
Syndicate
Crispr Therapeutics 4.211M share Secondary priced at $47.50 »

Goldman Sachs, Piper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

MDCA

MDC Partners

$4.55

0.25 (5.81%)

21:08
09/20/18
09/20
21:08
09/20/18
21:08
Hot Stocks
MDC Partners to evaluate strategic alternatives »

MDC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$101.71

0.16 (0.16%)

20:27
09/20/18
09/20
20:27
09/20/18
20:27
Hot Stocks
Guidewire sees 5-year target revenue of about $1.3B »

Sees % subscription of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AVMXY

Avita Medical

$0.00

(0.00%)

20:13
09/20/18
09/20
20:13
09/20/18
20:13
Hot Stocks
Avita Medical announces FDA approval of RECELL in burn treatment »

AVITA Medica announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.36

-0.03 (-1.26%)

20:05
09/20/18
09/20
20:05
09/20/18
20:05
Hot Stocks
Ladenburg Thalmann CEO to serve as chairman »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

MCD

McDonald's

$160.84

1.65 (1.04%)

18:32
09/20/18
09/20
18:32
09/20/18
18:32
Hot Stocks
McDonald's says dividend hike reinforces confidence in long-term targets »

McDonald's says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.